Breaking News, Collaborations & Alliances

Biohaven, Catalent Form Agreement

Will use Catalent's Zydis for the development of Biohaven's lead CGRP receptor antagonist product candidate

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biohaven Pharmaceutical has entered into an exclusive worldwide license agreement with Catalent U.K. Swindon Zydis Limited, a subsidiary of Catalent, Inc., to provide Catalent’s Zydis ODT (orally disintegrating tablet) fast-dissolving formulation for the development of Biohaven’s lead calcitonin gene-related peptide (CGRP) receptor antagonist product candidate, rimegepant. The agreement also provides exclusive rights for developing small molecule CGRP receptor antagonists with the Zy...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters